On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- BLET buys into Ancora’s promises
- SMART GC Ellis issues statement on LACMTA’s emergency declaration
- SMART-TD maintains support of current NS leadership
- Online fundraiser established for Local 821 officer’s family
- Ground broken on Brightline West — new rail jobs incoming!
- After FRA rule, Jared Cassity explains why we still need the Rail Safety Act
- ALERT for L.A.-area members — operator stabbing suspect at large
- SMART-TD wins SEPTA members’ security in their chosen craft
- Shining brightly in the midst of darkness
- Early-bird pricing for TD National Training Seminar ends April 30